Wockhardt

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE049B01025
NSEID: WOCKPHARMA
BSEID: 532300

INR

1,376.70

45.35 (3.41%)

BSENSE

Dec 05

BSE+NSE Vol: 22.37 lacs

{
  "main_header": {
    "sid": 256229,
    "name": "Wockhardt",
    "stock_name": "Wockhardt",
    "full_name": "Wockhardt Ltd",
    "name_url": "stocks-analysis/wockhardt",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,376.70",
    "chg": 45.35,
    "chgp": "3.41%",
    "dir": 1,
    "prev_price": "1,331.35",
    "mcapval": "22,521.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 532300,
    "symbol": "WOCKPHARMA",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE049B01025",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "22.37 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/wockhardt-256229-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Wockhardt overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-wockhardt-overvalued-or-undervalued-3745150",
        "imagepath": "",
        "date": "2025-12-04 08:11:24",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Examining Wockhardt’s Valuation Metrics</strong></p>\n<p>Wockhardt’s price-to-earnings (PE) ratio stands at an extraordinary 310.7, far exceeding typical industry standards and signalling a premium valuation. This figure dwarfs the PE ratios of many peers, including Sun Pharma Industries and Divi’s Laboratories, which themselves are considered expensive or very expensive. The company’s price-to-book value of 5.04 also suggests investors are paying a significant premium over its net asset value.</p>\n<p>Enterprise value multiples further highlight the stretched valuation. The EV to EBIT ratio is 108.98, and EV to EBITDA is 55.48, both substantially higher than industry averages. These elevated multiples imply that the market expects robust future earnings growth or unique competitive advantages..."
      },
      {
        "title": "Why is Wockhardt falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-wockhardt-fallingrising-3744850",
        "imagepath": "",
        "date": "2025-12-04 00:28:26",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Intraday Price Movement and Market Sentiment</strong></p>\n<p>Wockhardt’s shares touched an intraday low of ₹1,405.05, down nearly 6% from previous levels, signalling significant selling pressure. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting that sellers dominated the session. This decline came despite the stock outperforming the Sensex over the past week by a substantial margin, with a 10.67% gain compared to the benchmark’s 0.59% loss. However, the stock’s year-to-date performance remains slightly negative at -0.30%, underperforming the Sensex’s 8.92% rise.</p>\n<p>Technical indicators show the stock trading above its 5-day, 20-day, and 50-day moving averages, but below the 100-day and 200-day averages. This mixed technical pi..."
      },
      {
        "title": "Wockhardt Sees Robust Trading Activity Amidst Sector Outperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-surges-on-heavy-value-trading-and-institutional-interest-amid-sector-outperformance-3741225",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Wockhardt_most_active_equities_by_value_3741225.png",
        "date": "2025-12-02 10:00:09",
        "description": "Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 December 2025. The stock demonstrated notable trading volumes and value turnover, outperforming its sector peers and reflecting heightened investor interest and liquidity in the market."
      },
      {
        "title": "Is Wockhardt technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-wockhardt-technically-bullish-or-bearish-3739991",
        "imagepath": "",
        "date": "2025-12-02 08:24:29",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Overview of Recent Price Movements</strong></p>\n<p>Wockhardt’s current market price stands at ₹1,470.90, having surged from a previous close of ₹1,233.55. The stock’s intraday range on the latest trading session was between ₹1,226.15 and ₹1,480.25, indicating notable volatility. Over the past 52 weeks, the share price has oscillated between a low of ₹1,109.60 and a high of ₹1,870.00, reflecting a broad trading band that investors should consider when evaluating risk and reward.</p>\n<p><strong>Technical Trend Shift: From Bearish to Mildly Bearish</strong></p>\n<p>As of 1 December 2025, Wockhardt’s overall technical trend has transitioned from bearish to mildly bearish. This subtle shift suggests that while the stock remains under some selling pressure, the intensity of bearish momentum has eas..."
      },
      {
        "title": "Wockhardt Stock Analysis: Technical Momentum and Market Assessment",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-shares-surge-amid-mixed-technical-signals-and-momentum-shift-3739925",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Wockhardt_technicaldot_3739925.png",
        "date": "2025-12-02 08:02:47",
        "description": "Wockhardt’s recent trading activity reveals a notable shift in technical momentum, with key indicators signalling a transition from a bearish stance to a more nuanced mildly bearish outlook. The stock’s price movement, combined with mixed signals from MACD, RSI, and moving averages, offers investors a complex picture amid a volatile market backdrop."
      },
      {
        "title": "How has been the historical performance of Wockhardt?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-wockhardt-3739168",
        "imagepath": "",
        "date": "2025-12-01 23:00:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Revenue and Operating Performance Trends</strong></p>\n<p>Wockhardt's net sales have experienced variability, with figures peaking at ₹3,565 crore in March 2019 before declining and fluctuating in subsequent years. The fiscal year ending March 2025 recorded net sales of ₹3,012 crore, reflecting a modest recovery from the previous year’s ₹2,798 crore. This oscillation in revenue highlights the competitive pressures and market dynamics faced by the pharmaceutical company.</p>\n<p>Operating profit margins excluding other income have shown a gradual improvement, reaching 13.05% in March 2025 compared to a low of 1.39% in the prior year. The operating profit (PBDIT) excluding other income rose significantly to ₹393 crore in the latest fiscal year from ₹39 crore in March 2024, signalling enhanced op..."
      },
      {
        "title": "Wockhardt Sees High-Value Trading Amidst Volatile Market Activity",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-surges-on-heavy-value-trading-amid-institutional-interest-3738715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Wockhardt_most_active_equities_by_value_3738715.png",
        "date": "2025-12-01 13:00:08",
        "description": "Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 1 December 2025. The stock demonstrated significant price movement and trading volume, reflecting heightened investor interest and notable liquidity in a volatile market environment."
      },
      {
        "title": "Wockhardt Hits Day High with Strong Intraday Surge",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/wockhardt-hits-day-high-with-765-intraday-surge-on-1-dec-2025-3738661",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/Wockhardt_priceRelatedfactors_3738661.png",
        "date": "2025-12-01 11:46:38",
        "description": "Wockhardt recorded a notable intraday rally on 1 December 2025, reaching its highest price point of the day amid a broader positive market environment. The pharmaceutical company’s shares outpaced sector and benchmark indices, reflecting a significant shift in trading momentum after a brief period of decline."
      },
      {
        "title": "Wockhardt’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/wockhardt-downgraded-to-strong-sell-amid-technical-weakness-and-valuation-concerns-3727578",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/Wockhardt_mojoScore_3727578.png",
        "date": "2025-11-25 08:10:39",
        "description": "Wockhardt’s recent market evaluation reveals a complex interplay of financial performance and technical indicators, prompting a revision in the company’s assessment. While the pharmaceutical firm posted strong quarterly results, several long-term fundamentals and technical trends suggest a cautious outlook for investors."
      }
    ],
    "total": 376,
    "sid": "256229",
    "stock_news_url": "https://www.marketsmojo.com/news/wockhardt-256229"
  },
  "announcements": [
    {
      "caption": "Clarification sought from Wockhardt Ltd",
      "datetime": "02-Dec-2025",
      "details": "The Exchange has sought clarification from Wockhardt Ltd on December 2 2025 with reference to Movement in Volume.<BR><BR>The reply is awaited.",
      "source": "BSE"
    },
    {
      "caption": "Reply To Email Related To Volume Movement",
      "datetime": "02-Dec-2025",
      "details": "In response to your captioned letter dated 02.12.2025 we would like to state that we have reviewed and verified the relevant internal records operations and developments and hereby confirm that there is no information/announcement or events which in our opinion has a bearing on price/volume movement which require disclosure under Reg. 30 of SEBI Listing Regulations.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Press Release / Media Release",
      "datetime": "01-Dec-2025",
      "details": "Pursuant to Regulation 30 of Listing Regulations please find enclosed Press Release- US FDA Accepts Wockhardts New Drug Application for Breakthrough Antibiotic Zaynich.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Wockhardt Ltd has declared <strong>200%</strong> dividend, ex-date: 17 Nov 16",
          "dt": "2016-11-17",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "",
      "data": [
        {
          "txt": "Wockhardt Ltd has announced <strong>3:10</strong> rights issue, ex-date: 08 Mar 22",
          "dt": "2022-03-08",
          "middle_text": "Rights Issue"
        }
      ]
    }
  ]
}

News and Views

Is Wockhardt overvalued or undervalued?

2025-12-04 08:11:24

Examining Wockhardt’s Valuation Metrics

Wockhardt’s price-to-earnings (PE) ratio stands at an extraordinary 310.7, far exceeding typical industry standards and signalling a premium valuation. This figure dwarfs the PE ratios of many peers, including Sun Pharma Industries and Divi’s Laboratories, which themselves are considered expensive or very expensive. The company’s price-to-book value of 5.04 also suggests investors are paying a significant premium over its net asset value.

Enterprise value multiples further highlight the stretched valuation. The EV to EBIT ratio is 108.98, and EV to EBITDA is 55.48, both substantially higher than industry averages. These elevated multiples imply that the market expects robust future earnings growth or unique competitive advantages...

Why is Wockhardt falling/rising?

2025-12-04 00:28:26

Intraday Price Movement and Market Sentiment

Wockhardt’s shares touched an intraday low of ₹1,405.05, down nearly 6% from previous levels, signalling significant selling pressure. The weighted average price indicates that a larger volume of shares traded closer to the day’s low, suggesting that sellers dominated the session. This decline came despite the stock outperforming the Sensex over the past week by a substantial margin, with a 10.67% gain compared to the benchmark’s 0.59% loss. However, the stock’s year-to-date performance remains slightly negative at -0.30%, underperforming the Sensex’s 8.92% rise.

Technical indicators show the stock trading above its 5-day, 20-day, and 50-day moving averages, but below the 100-day and 200-day averages. This mixed technical pi...

Wockhardt Sees Robust Trading Activity Amidst Sector Outperformance

2025-12-02 10:00:09

Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 2 December 2025. The stock demonstrated notable trading volumes and value turnover, outperforming its sector peers and reflecting heightened investor interest and liquidity in the market.

Is Wockhardt technically bullish or bearish?

2025-12-02 08:24:29

Overview of Recent Price Movements

Wockhardt’s current market price stands at ₹1,470.90, having surged from a previous close of ₹1,233.55. The stock’s intraday range on the latest trading session was between ₹1,226.15 and ₹1,480.25, indicating notable volatility. Over the past 52 weeks, the share price has oscillated between a low of ₹1,109.60 and a high of ₹1,870.00, reflecting a broad trading band that investors should consider when evaluating risk and reward.

Technical Trend Shift: From Bearish to Mildly Bearish

As of 1 December 2025, Wockhardt’s overall technical trend has transitioned from bearish to mildly bearish. This subtle shift suggests that while the stock remains under some selling pressure, the intensity of bearish momentum has eas...

Wockhardt Stock Analysis: Technical Momentum and Market Assessment

2025-12-02 08:02:47

Wockhardt’s recent trading activity reveals a notable shift in technical momentum, with key indicators signalling a transition from a bearish stance to a more nuanced mildly bearish outlook. The stock’s price movement, combined with mixed signals from MACD, RSI, and moving averages, offers investors a complex picture amid a volatile market backdrop.

How has been the historical performance of Wockhardt?

2025-12-01 23:00:55

Revenue and Operating Performance Trends

Wockhardt's net sales have experienced variability, with figures peaking at ₹3,565 crore in March 2019 before declining and fluctuating in subsequent years. The fiscal year ending March 2025 recorded net sales of ₹3,012 crore, reflecting a modest recovery from the previous year’s ₹2,798 crore. This oscillation in revenue highlights the competitive pressures and market dynamics faced by the pharmaceutical company.

Operating profit margins excluding other income have shown a gradual improvement, reaching 13.05% in March 2025 compared to a low of 1.39% in the prior year. The operating profit (PBDIT) excluding other income rose significantly to ₹393 crore in the latest fiscal year from ₹39 crore in March 2024, signalling enhanced op...

Wockhardt Sees High-Value Trading Amidst Volatile Market Activity

2025-12-01 13:00:08

Wockhardt Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has emerged as one of the most actively traded stocks by value on 1 December 2025. The stock demonstrated significant price movement and trading volume, reflecting heightened investor interest and notable liquidity in a volatile market environment.

Wockhardt Hits Day High with Strong Intraday Surge

2025-12-01 11:46:38

Wockhardt recorded a notable intraday rally on 1 December 2025, reaching its highest price point of the day amid a broader positive market environment. The pharmaceutical company’s shares outpaced sector and benchmark indices, reflecting a significant shift in trading momentum after a brief period of decline.

Wockhardt’s Market Assessment Reflects Mixed Signals Amidst Financial and Technical Shifts

2025-11-25 08:10:39

Wockhardt’s recent market evaluation reveals a complex interplay of financial performance and technical indicators, prompting a revision in the company’s assessment. While the pharmaceutical firm posted strong quarterly results, several long-term fundamentals and technical trends suggest a cautious outlook for investors.

View All News

Announcement

Clarification sought from Wockhardt Ltd

02-Dec-2025 | Source : BSE

The Exchange has sought clarification from Wockhardt Ltd on December 2 2025 with reference to Movement in Volume.

The reply is awaited.

Reply To Email Related To Volume Movement

02-Dec-2025 | Source : BSE

In response to your captioned letter dated 02.12.2025 we would like to state that we have reviewed and verified the relevant internal records operations and developments and hereby confirm that there is no information/announcement or events which in our opinion has a bearing on price/volume movement which require disclosure under Reg. 30 of SEBI Listing Regulations.

Announcement under Regulation 30 (LODR)-Press Release / Media Release

01-Dec-2025 | Source : BSE

Pursuant to Regulation 30 of Listing Regulations please find enclosed Press Release- US FDA Accepts Wockhardts New Drug Application for Breakthrough Antibiotic Zaynich.